

DECIPHER PROSTATE RP

WHAT IS THE DECIPHER TEST?

Decipher is a tumor-based test that provides genomic information to help you and your physician make decisions about your care



DECIPHER RP

- Performed on your prostate after surgery (after it has been removed)
- May help determine which men after prostate surgery can be safely monitored and which men need additional treatment



ACCESS FOR ALL PATIENTS

- Covered by Medicare
- Covered by select private insurers
- Generous financial assistance program for patients - Decipher Assist

Contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com



Decipher Biosciences
Information for Life

To learn more about Decipher, contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com

Copyright © 2020 Decipher Biosciences, Inc.
Testing is performed by Decipher Corp., a Decipher Biosciences company

DECIPHER PROSTATE RP

AFTER SURGERY



DECIPHER PROSTATE RP

Decipher RP helps you and your doctor decide next steps in your prostate cancer care

DECIPHER PROSTATE RP

NOT ALL PROSTATE CANCERS ARE ALIKE

THE DECIPHER® TEST:

- Tells you how likely your cancer is to spread (or metastasize) beyond your prostate
- Categorizes most patients into Decipher high or low risk, to help determine what to do after your prostate has been removed (radical prostatectomy)

Decipher Test Result	Treatment After Your Prostate Cancer Surgery	Treatment for PSA Rise (Biochemical Recurrence)
Low Risk	May be safely managed with observation until PSA rise (if any) ^{1,2}	Excellent prognosis with salvage radiation and may avoid concurrent hormone therapy ³
High Risk	May benefit from early radiation ^{1,2}	May require intensification of therapy beyond radiation ³

ANSWER THE FOLLOWING QUESTIONS TO DETERMINE IF DECIPHER® IS RIGHT FOR YOU:

Did your doctor indicate that any of the following applied to you after radical prostatectomy (prostate removal) to treat your prostate cancer?

Medicare Indications

	Y	N
Positive surgical margins	<input type="checkbox"/>	<input type="checkbox"/>
Extraprostatic extension	<input type="checkbox"/>	<input type="checkbox"/>
Seminal Vesicle Invasion	<input type="checkbox"/>	<input type="checkbox"/>
Bladder Neck Invasion	<input type="checkbox"/>	<input type="checkbox"/>
Has your PSA started to rise after surgery?	<input type="checkbox"/>	<input type="checkbox"/>

If you answered **yes** to any of the questions above, then Decipher may play a role in determining if and when you need additional therapy after surgery.



This test is covered by Medicare and select private insurers. We have a generous financial aid program, Decipher Assist, for qualified patients.

References

1. Den, R. B. et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. *J. Clin. Oncol.* 33, 944–951 (2015).
2. Den, R. B. et al. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 89, 1038–1046 (2014).
3. Freedland, S. J. et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. *Eur. Urol.* 70, 588–596 (2016).



Contact your doctor to find out how Decipher might play a role in your treatment planning or contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com